In the international business community, few law enforcement matters in recent years have attracted as much attention as the Foreign Corrupt Practices Act. FCPA enforcement - conducted by both the U.S. Department of Justice and the Securities and Exchange Commission - has been intense and increasing over the last decade. The total numbers of FCPA actions brought by both agencies have risen from a mere five in 2004 to between 40 and 74 in the last three years. This trend has particular relevance for Triangle companies, including pharmaceutical companies and clinical-research organizations.
To read the full article by Brooks Pierce attorney and former SEC staffer David Smyth, see attached document.